Insider · CIK 0001600865

Neal James R

Reports to the SEC for 6 companies · VERO BEACH, FL

sec.gov

Transactions

Companies

Filings

CIK

0001600865

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-26	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+62.2K sh	—	—	67,470
2026-06-26	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockM Exercise/Conversion	Director	MExercise/Conversion	−203 sh	—	—	5,249
2026-06-26	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+203 sh	—	—	1,021
2026-03-31	PCSAProcessa Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+789 sh	$2.54	+$2,000.115	818
2025-12-16	AKTXAkari Therapeutics Plc · Warrants to purchase American Depositary Shares ("ADRs")P Purchase	Director	PPurchase	+2,473 sh	—	—	2,473
2025-12-16	AKTXAkari Therapeutics Plc · Pre-Funded Warrants to purchase ADRsP Purchase	Director	PPurchase	+2,473 sh	$0.40	+$999.339	2,473
2025-12-16	AKTXAkari Therapeutics Plc · Pre-Funded Warrants to purchase ADRsP Purchase	Director	PPurchase	+3,093 sh	$0.40	+$1,249.881	3,093
2025-12-16	AKTXAkari Therapeutics Plc · Warrants to purchase ADRsP Purchase	Director	PPurchase	+3,093 sh	—	—	3,093
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+300K sh	—	—	300,000
2025-10-01	PCSAProcessa Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Director	AAward	+100K sh	—	—	100,000
2025-07-24	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockA Award	Director	AAward	+175K sh	—	—	206,505
2025-03-20	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+175K sh	—	—	175,000
2025-03-20	AKTXAkari Therapeutics Plc · Stock Option (Right to Buy)A Award	Director	AAward	+225K sh	—	—	225,000
2025-03-06	AKTXAkari Therapeutics Plc · Series A Warrants (Right to Buy)A Award	Director	AAward	+4,464 sh	$1.12	+$4,999.68	4,464
2025-03-06	AKTXAkari Therapeutics Plc · Series B Warrants (Right to Buy)A Award	Director	AAward	+4,464 sh	$1.12	+$4,999.68	4,464
2025-03-06	AKTXAkari Therapeutics PlcA Award	Director	AAward	+4,464 sh	$1.12	+$4,999.68	36,271
2025-01-09	AKTXAkari Therapeutics PlcA Award	Director	AAward	+8M sh	$0.00	+$4,800	32,216,000
2024-12-23	AKTXAkari Therapeutics PlcA Award	Director	AAward	+2M sh	$0.00	+$1,000	24,216,000
2024-11-14	Peak Bio, Inc.C Conversion	Director	CConversion	+37.9K sh	—	—	37,850
2024-11-14	Peak Bio, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−500K sh	—	—	0
2024-11-14	Peak Bio, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−37.9K sh	—	—	0
2024-11-14	Peak Bio, Inc.Convertible NotesC Conversion	Director	CConversion	—	—	—	0
2024-11-14	Peak Bio, Inc.Warrant (Right to Purchase)D Disposition to Issuer	Director	DDisposition to Issuer	−33.3K sh	—	—	0
2024-09-03	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockA Award	Director	AAward	+31.2K sh	—	—	31,206
2024-09-03	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockA Award	Director	AAward	+31.2K sh	—	—	36,275
2024-02-09	PALIPALISADE BIO, INC. · Common Stock OptionsM Exercise/Conversion	Director	MExercise/Conversion	+6,880 sh	—	—	6,880
2024-02-09	PALIPALISADE BIO, INC. · Common Stock OptionsM Exercise/Conversion	Director	MExercise/Conversion	−6,880 sh	—	—	0
2024-02-09	PALIPALISADE BIO, INC. · Common Stock OptionsM Exercise/Conversion	Director	MExercise/Conversion	+12.2K sh	—	—	12,160
2024-02-09	PALIPALISADE BIO, INC. · Common Stock OptionsM Exercise/Conversion	Director	MExercise/Conversion	−12.2K sh	—	—	0
2024-02-09	PALIPALISADE BIO, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−5,820 sh	—	—	0
2024-02-09	PALIPALISADE BIO, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−5,100 sh	—	—	0
2024-02-09	PALIPALISADE BIO, INC.M Exercise/Conversion	Director	MExercise/Conversion	+5,820 sh	—	—	10,920
2024-02-09	PALIPALISADE BIO, INC.M Exercise/Conversion	Director	MExercise/Conversion	+5,100 sh	—	—	5,100
2023-11-21	PALIPALISADE BIO, INC. · Common Stock OptionsA Award	Director	AAward	+6,880 sh	—	—	6,880
2023-11-21	PALIPALISADE BIO, INC. · Restricted Stock UnitsA Award	Director	AAward	+5,820 sh	—	—	5,820
2023-06-27	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockM Exercise/Conversion	Director	MExercise/Conversion	−14.4K sh	—	—	0
2023-06-27	PCSAProcessa Pharmaceuticals, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+14.4K sh	—	—	14,407
2023-06-27	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockA Award	Director	AAward	+101K sh	—	—	101,365
2023-06-11	PALIPALISADE BIO, INC. · Common Stock OptionsA Award	Director	AAward	+12.2K sh	—	—	12,160
2023-06-11	PALIPALISADE BIO, INC. · Restricted Stock UnitsA Award	Director	AAward	+5,100 sh	—	—	5,100
2023-04-28	Peak Bio, Inc.Convertible NotesA Award	Director	AAward	—	$20004.00	—	—
2023-04-28	Peak Bio, Inc.Warrant (Right to Purchase)A Award	Director	AAward	+33.3K sh	—	—	33,340
2022-07-19	PCSAProcessa Pharmaceuticals, Inc. · Restricted StockA Award	Director	AAward	+17.8K sh	—	—	17,797
2022-07-15	XOMA Royalty CorpS Sale	Director, CEO	SSale	−3,212 sh	$31.19	−$100K	12,727
2022-07-15	XOMA Royalty CorpS Sale	Director, CEO	SSale	−20.9K sh	$29.55	−$617K	15,939
2022-07-15	XOMA Royalty CorpM Exercise/Conversion	Director, CEO	MExercise/Conversion	+25K sh	$4.03	+$101K	36,822
2022-07-15	XOMA Royalty CorpS Sale	Director, CEO	SSale	−905 sh	$31.86	−$28.8K	11,822
2022-07-15	XOMA Royalty CorpStock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−25K sh	—	—	218,056
2022-03-23	XOMA Royalty CorpStock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−1,111 sh	—	—	102,800
2022-03-23	XOMA Royalty CorpS Sale	Director, CEO	SSale	−1,111 sh	$30.02	−$33.3K	11,822

Recent filings

Accepted (ET)
Jul 284
Neal James R0000897069-26-001552
SEC(opens sec.gov)
Jun 304
Neal James R0000897069-26-001468
SEC(opens sec.gov)
Apr 24
Neal James R0000897069-26-000781
SEC(opens sec.gov)
Mar 164
Neal James R0001493152-26-010304
SEC(opens sec.gov)
Oct 34
Neal James R0000897069-25-001561
SEC(opens sec.gov)
Sep 184/A
Neal James R0000897069-25-001496
SEC(opens sec.gov)
Jul 284
Neal James R0000897069-25-001211
SEC(opens sec.gov)
Mar 244
Neal James R0000950170-25-043940
SEC(opens sec.gov)
Mar 104
Neal James R0000950170-25-036485
SEC(opens sec.gov)
Jan 104
Neal James R0000950170-25-004300
SEC(opens sec.gov)
Dec 264
Neal James R0000950170-24-140431
SEC(opens sec.gov)
Nov 184
Neal James R0000950170-24-128150
SEC(opens sec.gov)

Companies

Address

C/O PROCESSA PHARMACEUTICALS, INC. 601 21ST STREET SUITE 300

VERO BEACH, FL, 32960